Nautilus Biotechnology (NAUT) Cash & Equivalents Growth (3y) (2023 - 2026)

Nautilus Biotechnology (NAUT) Cash & Equivalents Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Nautilus Biotechnology 212.11 Mn 116.24 Mn - -45.12%

Historic Data

Download Data
DateValue
Mar 31, 2026 -45.12%
Dec 31, 2025 -52.35%
Sep 30, 2025 -49.82%
Jun 30, 2025 -45.28%
Mar 31, 2025 -43.94%
Dec 31, 2024 -46.99%
Sep 30, 2024 -71.49%
Jun 30, 2024 -55.81%
Mar 31, 2024 235.39%
Dec 31, 2023 -19.08%
Sep 30, 2023 311.31%